iBio, Inc. (IBIO)
NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
2.150
+0.040 (1.90%)
At close: Jul 19, 2024, 4:00 PM
2.010
-0.140 (-6.51%)
Pre-market: Jul 22, 2024, 5:59 AM EDT
iBio, Inc. Revenue
iBio, Inc. had revenue of $50.00K in the twelve months ending March 31, 2024.
Revenue (ttm)
$50.00K
Revenue Growth
n/a
P/S Ratio
370.82
Revenue / Employee
$1,923
Employees
26
Market Cap
18.54M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 0 | - | - |
Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
Jun 30, 2020 | 1.64M | -380.00K | -18.83% |
Jun 30, 2019 | 2.02M | 1.57M | 354.50% |
Jun 30, 2018 | 444.00K | 50.00K | 12.69% |
Jun 30, 2017 | 394.00K | -554.00K | -58.44% |
Jun 30, 2016 | 948.00K | -903.00K | -48.78% |
Jun 30, 2015 | 1.85M | 1.65M | 802.93% |
Jun 30, 2014 | 205.00K | -802.00K | -79.64% |
Jun 30, 2013 | 1.01M | -270.00K | -21.14% |
Jun 30, 2012 | 1.28M | 756.92K | 145.54% |
Jun 30, 2011 | 520.08K | - | - |
Jun 30, 2010 | 0 | - | - |
Jun 30, 2009 | 1.18M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aytu BioPharma | 93.76M |
Biotricity | 12.06M |
VBI Vaccines | 9.41M |
Aspira Women's Health | 8.99M |
Synlogic | 3.21M |
Aeterna Zentaris | 2.37M |
Lyra Therapeutics | 1.68M |
IBIO News
- 7 weeks ago - iBio Closes Sale of Manufacturing Facility in Texas - GlobeNewsWire
- 2 months ago - iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - iBio stock nearly tripled on Wednesday: here's why - Invezz
- 4 months ago - iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases - GlobeNewsWire
- 4 months ago - iBio Announces $15.0 Million Private Placement - GlobeNewsWire
- 5 months ago - iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka - GlobeNewsWire
- 6 months ago - iBio Announces Participation in 23rd Annual PepTalk Conference - GlobeNewsWire
- 6 months ago - Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI) - Benzinga